Guardant Health Reaches New 52-Week High of $133.70

Guardant Health, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 133.70 on May 28, 2026. This achievement marks a remarkable increase from its 52-week low of USD 38.03, showcasing a substantial year-over-year performance of 343.18%. In comparison, the S&P 500 has seen a more modest gain of 28.45% during the same period. The company's market capitalization stands at USD 11,435 million, reflecting its solid position within the industry. Despite being loss-making, Guardant Health has demonstrated impressive financial metrics, including a return on equity of 427.38%. However, it is noteworthy that the company does not offer a dividend, and its price-to-book ratio is reported at -115.15, indicating unique financial dynamics. As Guardant Health continues to navigate the competitive landscape of pharmaceuticals and biotechnology, its recent performance highlights its potential resilience and adaptability in a rapidly evolving market.